Back to results
US 8,618,157 B2Granted
Pharmaceutical formulation
AssigneeAlphapharm Pty Ltd
InventorsBrett Antony Mooney, Panagiotis Keramidas
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.
Claims21
A pharmaceutical composition comprising:
- a. a 5-HT1 agonist selected from the group consisting of a triptan, ergotamine, 5carboxamidotryptamine, 3-[(N-2-methoxyethyl) pyrrolidine-2R-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4S-ylmethyl)-1H-indole, 5-(2-oxo-1,3-oxazolidin-4S-ylmethyl)-3-(pyrrolidine-2R-ylmethyl-1H-indole, 3-[N-methylpyrrolidine-2R-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4R,S-ylmethyl)-1H-indole, and pharmaceutically acceptable salts thereof;
- b. a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of acidic NSAIDs, long acting NSAIDs, and COX-2 inhibitors;
- and
- c. a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone, hydroxypropylcellulose, low substituted hydroxypropylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, sodium starch glycollate, docusate sodium, pregelatinized starch, colloidal silicon dioxide, sodium citrate, polyethylene glycol, polyoxyethylene, magnesium carbonate, calcium carbonate or sodium bicarbonate, wherein the 5-HT1 agonist and the NSAID are present in the pharmaceutical composition in a single phase, the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, and said composition optionally comprises one or more other pharmaceutically acceptable excipients.
1 more element
A pharmaceutical composition comprising:
- a 5-HT1 agonist, wherein the 5-HT1 agonist is sumatriptan succinate;
- a non-steroidal anti-inflammatory drug (NSAID), wherein the NSAID is naproxen sodium;
- and
- a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone, and further wherein the 5-HT1 agonist and the NSAID are present in the pharmaceutical composition in a single phase, the disintegrant comprises between about 30 to about 50% w/w based on the weight of the composition, and the composition optionally comprises one or more other pharmaceutically acceptable excipients.
1 more element
Dependencies are inferred from the claim text.